Ebos Group Limited · NZX:EBO
Ebos — Macquarie Australia Conference 2020
22 slides from Ebos's conference presentation, May 5, 2020
Slide 1: Macquarie Australia Conference Presentation
5 May 2020 For personal use only NZX/ASX Code: EBO Macquarie Australia Conference Presentation Please see attached a copy of a presentation to be delivered at the Macquarie Australia Conference today. Authorised for lodgement with NZX and ASX by: John Cullity Chief Executive Officer EBOS Group Limit
Slide 2: Macquarie Australia Conference
For personal use only MACQUARIE AUSTRALIA CONFERENCE John Cullity – Chief Executive Officer 5 May 2020
Slide 3: Disclaimer
DISCLAIMER The information in this presentation was prepared by EBOS Group Ltd (EBOS) with due care and attention. However, the information is For personal use only supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or r
Slide 4: Company Snapshot
COMPANY SNAPSHOT EBOS Group is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading For personal use only marketer and distributor of recognised consumer products and animal care brands First Half
Slide 5: Share Price Performance
SHARE PRICE PERFORMANCE EBOS share price appreciation of 134% over five years For personal use only $30 $25 EBO.NZX +134% $20 $15 $10 S&P/ASX100 –11% $5 $0 2015 2016 2017 2018 2019 2020 Source: Nasdaq (rebased to EBO.NZX for comparative purposes) Date range: 5 years to 1 May 2020 4
Slide 6: Group Overview
GROUP OVERVIEW EBOS is a diversified health care and animal care products group with leading brands For personal use only Description Brands Community Pharmacy – • Pharmaceutical wholesaler to ~3500+ pharmacies in Australia & New Zealand Wholesale Community Pharmacy – • ~1300+ Australian pharmacies
Slide 7: Scale & Leading Market Positions
SCALE & LEADING MARKET POSITIONS EBOS generates >A$7bn1 of revenue and has leading market positions across Australia and New Zealand For personal use only Community Pharmacy – • #1 wholesaler to pharmacies • #1 wholesaler to pharmacies Wholesale Community • One of the largest aggregated retail Pharm
Slide 8: Group Diversity
GROUP DIVERSITY EBOS is a diverse group across sectors and geographies and operates across the value chain For personal use only Sector and segment mix1 Healthcare geographic mix2 13% 87% 20% 80% 13% 5% 49% 9% 24% Health Care Pharmacy Australia (Wholesale and retail) Australia NZ Animal Care Institu
Slide 9: H1 FY20 Highlights
H1 FY20 HIGHLIGHTS Group revenue increased by 25.2% in H1 FY20 evidencing the strength of our portfolio of For personal use only businesses with a substantial uplift in Pharmacy Wholesale and strong performances from TerryWhite Chemmart, Institutional Healthcare and Healthcare Logistics The Australi
Slide 10: Financial Performance
FINANCIAL PERFORMANCE EBOS has delivered significant shareholder value with a strong ROCE and consistent growth For personal use only EBITDA1 (A$m) Dividends Per Share1 (NZ$ cents) H2 H1 H1 H2 71.5 250.1 261.6 68.5 228.2 63.0 207.7 58.5 123.8 130.2 35.5 37.0 111.8 33.0 103.3 32.5 126.3 131.4 149.0 3
Slide 11: Strategic Approach
STRATEGIC APPROACH Our Healthcare and Animal Care strategic focus is centred on: For personal use only Disciplined Capital Leading Market Positions Investing for Growth Management Establish and further Capex: Maintain and Cash generation to drive strengthen our leading extend our market furthe
Slide 12: Investing for Growth and Returns
INVESTING FOR GROWTH AND RETURNS EBOS has a proven track record of value accretive investments For personal use only Investment strategy Shareholder outcomes Acquire businesses aligned to our strategy EPS growth Invest in automated distribution network solutions to extend DPS growth our mark
Slide 13: Strategic Focus Areas for Growth
STRATEGIC FOCUS AREAS FOR GROWTH With the right mix of businesses that deliver consistency in our performance and with a strong balance sheet, we aim to: For personal use only Continue to execute on both organic initiatives and strategic value accretive acquisitions. Leverage our position as the low
Slide 14: COVID-19 Market Update
COVID-19 MARKET UPDATE On 21 April, EBOS advised of strong trading conditions to 31 March 2020 and confirmed its balance sheet strength For personal use only Trading Conditions Our wholesale, distribution and retail Healthcare businesses are essential services and critical in ensuring continued an
Slide 15: Questions
For personal use only QUESTIONS
Slide 16: Appendix
For personal use only APPENDIX
Slide 17: H1 FY20 Financial Performance
H1 FY20 FINANCIAL PERFORMANCE Significant revenue increase of For personal use only A$m H1 FY20 H1 FY19 Var$ Var% 25.2% primarily due to growth in Underlying Results ¹ Pharmacy Wholesale, TerryWhite Revenue 4,376.1 3,496.5 879.6 25.2% Chemmart, Institutional Healthcare Gross Operating Revenue 449.
Slide 18: Cash Flow
CASH FLOW For personal use only A$m H1 FY20 H1 FY19 Var$ Var% Statutory Cash Flow including IFRS 16 Leases EBITDA 167.2 122.6 44.6 36.4% Net interest paid (15.4) (12.4) (3.1) Tax paid (32.6) (25.7) (6.9) Net working capital and other movements (45.0) (44.3) (0.7) Cash from Operating activities 74.2
Slide 19: Net Debt and Maturity Profile
NET DEBT AND MATURITY PROFILE Net Debt and Net Debt : EBITDA ratio 1 Debt Maturity Profile – facility limits 1 For personal use only Net Debt1 of $392m at December 2019, At 31 December 2019, gross drawn debt1 was with a Net Debt : EBITDA1 ratio of 1.41x $666m or 64% of total facility limits. (1.
Slide 20: Healthcare Segment
HEALTHCARE SEGMENT Significant growth in Australia from a strong underlying trading performance For personal use only Healthcare growth in revenue of 26.1% and A$m H1 FY20 H1 FY19 Var$ Var% Underlying EBITDA of 16.3% was driven by Revenue 4,165.5 3,304.2 861.3 26.1% the performances of our Communi
Slide 21: Animal Care Segment
ANIMAL CARE SEGMENT Strong Revenue and Underlying EBITDA performance reflecting continued growth in our key brands For personal use only A$m H1 FY20 H1 FY19 Var$ Var% Underlying EBITDA and Underlying EBITDA % Revenue 210.6 192.3 18.3 9.5% Underlying EBITDA 25.7 24.3 1.4 5.7% Underlying EBITDA% 12.2%
Slide 22: www.ebosgroup.com
For personal use only www.ebosgroup.com